AZD-5423
AZD-5423 is a nonsteroidal glucocorticoid and phase II experimental drug being developed by AstraZeneca and disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat respiratory diseases and in particular…
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
AZD-5423 is a nonsteroidal glucocorticoid and phase II experimental drug being developed by AstraZeneca and disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat respiratory diseases and in particular chronic obstructive pulmonary disease. It has completed a phase II clinical trial.
See also
Dagrocorat Fosdagrocorat Mapracorat
External links
AZD-5423 - AdisInsight
Text derived from https://en.wikipedia.org/w/index.php?oldid=1371300503 under CC BY-SA 4.0; modifications have been made.